Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated ...

Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.

Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings ...

The term “food noise” has emerged alongside the popularity of glucagon-like peptide-1receptor agonists — known as GLP-1 ...

His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity ...

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading Into 2026NEWARK, DE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- ...

Patients who stopped taking GLP-1 weight-loss medications regained weight four times as fast as those using alternative ...

According to an article posted by the Yale School of Medicine in July 2024, “The first drug in a class known as GLP-1 ...

President Donald Trump isn’t opposed to using weight-loss drugs. Trump, 79, addressed concerns about his health during a ...

Cardiometabolic markers — including blood pressure and cholesterol — also returned to baseline levels about 16 months after ...

Recent estimates suggest that roughly 60 per cent of cats and dogs in the US are obese. Read more at straitstimes.com. Read ...

GLP-1 meds are are highly effective at treating diabetes, obesity and other conditions. But when people stop using them, the ...